CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 13 No. 10 5
Pages: 1  2  3  4  
Next
 

3D Treatment Planning and Intensity-Modulated Radiation Therapy

By

James A. Purdy, PhD
Radiation Oncology Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

| October 1, 1999
Three-dimensional (3D) image-based treatment planning and new delivery technologies have spurred the implementation of external beam radiation therapy techniques, in which the high-dose region is conformed much more closely to the target volume than previously possible, thus reducing the volume of normal tissues receiving a high dose. This form of external beam irradiation is referred to as 3D conformal radiation therapy (3DCRT). 3DCRT is not just an add-on to the current radiation oncology process; it represents a radical change in practice, particularly for the radiation oncologist. Defining target volumes and organs at risk in 3D by drawing contours on CT images on a slice-by-slice basis, as opposed to drawing beam portals on a simulator radiograph, can be challenging, because radiation oncologists are generally not well trained in cross-sectional imaging. Currently, the 3DCRT approach will increase the time and effort required by physicians inexperienced with 3D treatment planning. Intensity-modulated radiation therapy (IMRT) is a more advanced form of 3DCRT, but there is considerable developmental work remaining. The instrumentation and methods used for IMRT quality assurance procedures and testing are not well established. Computer optimization cost functions are too simplistic, and thus time-consuming. Subjective plan evaluation by the radiation oncologist is still the norm. In addition, many fundamental questions regarding IMRT remain unanswered. For example, the radiobiophysical consequences of altered time-dose-fraction are unknown. Also, the fact that there is much greater dose heterogeneity for both the target and normal critical structures with IMRT compared to traditional irradiation techniques challenges current radiation oncology planning principles. However, this new process of planning and treatment delivery shows significant potential for improving the therapeutic ratio. In addition, while inefficient today, these systems, when fully developed, will improve the efficiency with which external beam radiation therapy can be planned and delivered, thus lowering costs. [ONCOLOGY 13(Suppl 5):155-168, 1999]


Introduction

Three-dimensional radiation therapy treatment planning (3DRTTP) systems have spurred the implementation of external beam radiation therapy techniques, in which the high-dose region can be conformed much more closely to the cancer patient’s target volume than was previously possible, thus reducing the volume of normal tissues receiving a high dose. This form of external beam irradiation is referred to as three-dimensional conformal radiation therapy (3DCRT), and its development and clinical use are discussed in considerable detail elsewhere.[1,2] Several groups have already reported on their early clinical experience with 3DCRT for the treatment of prostate cancer, and the results are encouraging.[3-5]

Three-dimensional planning is not just an addition to the current radiation oncology planning process, but rather represents a radical change in practice, particularly for the radiation oncologist. The two-dimensional (2D) treatment planning approach emphasizes the use of a conventional simulator for designing beam portals, based on standardized beam arrangement techniques applied to whole classes of comparable patients. Three-dimensional treatment planning emphasizes a virtual simulation, image-based approach for objectively defining tumor and critical structure volumes for the individual patient.

The use of the terms 2D and 3D as descriptors for the planning process has caused some confusion in the radiation oncology community. One should recognize that planning the cancer patient’s treatment is, and always has been, a 3D problem, and 2D planning refers to the process and tools used. Three-dimensional treatment planning does not require the use of “noncoplanar” beams, a common misconception. Noncoplanar beams have been used for years in selected sites such as breast cancer, even though 2D treatment planning systems could not accurately account for the geometry. Clearly, noncoplanar breast tangential fields represented on a 2DRTTP system by a single, or at most a few, slices cannot be considered a 3D treatment plan. Radiation oncologists will be able to transition to 3D planning much more easily if they approach 3DRTTP as a new treatment planning process, emphasizing image-based target volume design rather than as a reflection of a particular beam configuration.

One of the important factors contributing to the current 3D process is the standardization of nomenclature, published in the International Commission on Radiation Units and Measurements (ICRU) Report 50.[6] This report has provided a language and a way of thinking about the problem for defining the volume of known tumor, suspected microscopic spread, and marginal volumes necessary to account for set-up variations and organ and patient motion. Figure 1 illustrates the ICRU 50 formal definitions for the gross tumor volume, clinical target volume, planning target volume, and organs at risk. Some brief discussion on the use of the ICRU 50 methodology is presented in a later section. Also, the reader is referred to the literature for more details regarding the use of ICRU 50 nomenclature.[7,8]

Table 1 lists the various tasks that make up the 3D planning dose and delivery process in its current technology state. 3DCRT treatment plans generally use an increased number of radiation beams that are angled and shaped to conform to the planning target volume using the 3DRTTP system’s beam’s-eye view and room’s-eye view displays (Figures 2A and 2B). To improve the conformity of the dose distribution, conventional beam modifiers (eg, wedges or compensating filters) are sometimes used. This form of 3DCRT must now be referred to as “traditional” or “conventional” 3DCRT, because a more advanced form of 3DCRT, called intensity-modulated radiation therapy, is already emerging. Intensity-modulated radiation therapy can achieve even greater conformity by optimally modulating the radiation beam intensity (fluence) throughout each treatment field.[9]

These advances in radiation oncology technology are truly exciting and are occurring at a very rapid pace. However, as the implementation of 3D planning and dose delivery systems becomes more widespread, the radiation oncology team must understand that ensuring the safety and accuracy of this new modality is more difficult (in its current development state) than with the standard 2D process. Therefore, it is essential that the radiation oncology team stay well informed on the new technologies and maintain a strong commitment to a rigorous quality assurance program when this new treatment modality is implemented in the clinic. This article will update a previous review of advances in 3DRTTP and dose delivery.[10]

Advances In 3D Treatment Planning

Three-dimensional RTTP systems are currently going through a rapid transition period, having emerged from university-developed systems to Food and Drug Administration-approved commercially available systems in the early 1990s. These first-generation commercial systems provide specific functionality, such as virtual simulation or 3D external beam dose planning. Such limited functionality has resulted in clinics needing multiple treatment planning systems to provide for various high-tech treatment modalities, like virtual simulation, 3D external beam dose planning, high-dose-rate brachytherapy, prostate seed implant, and stereotactic radiosurgery. This is clearly not very satisfactory, resulting in increased costs and inefficiencies.

Over the next few years, the treatment planning system manufacturers will begin to combine these planning programs into a single integrated image-based 3DRTTP system that provides planning capability for multiple treatment modalities, resulting in considerable cost savings. In addition, we should soon see improved efficiencies based on the use of “intranets.” An intranet is a special type of internet-related technology with the potential to dramatically improve a radiation oncology clinic’s ability to use 3DRTTP. A radiation oncology clinic’s intranet will make use of client server (and browser) technology that will provide easy-to-use Windows-like displays, permitting users to easily navigate through multiple treatment planning and other clinical applications, data, and graphical displays using point-and-click technology. However, prior to further discussion on information technology, it is important to describe some of the improved features now readily available on 3DRTTP systems.

Imaging for 3D Planning

The development of powerful but relatively inexpensive computer systems has allowed the integration of computed tomography (CT)–based target volume and normal tissue definition with the process of radiation therapy treatment planning, creating an entirely new device, the CT simulator. The CT simulator differs in both purpose and function from the conventional simulator.[11,12] A typical CT simulation uses a helical CT scanner with localization software, a patient registration and laser marking system, and a dedicated computer workstation for virtual simulation and generation of digitally reconstructed radiographs.

Although the current generation of CT simulators provides powerful new 3D capabilities, several improvements in the hardware are still needed for treatment planning purposes because the CT scanner currently used was designed for diagnostic radiology use. Specifically, a larger CT gantry aperture is needed. Current scanners have a 70-cm diameter, which limits some treatment set-ups. Also, the CT reconstruction size needs to be larger (currently only a 52-cm diameter is provided). CT simulator couch tops that mimic the geometry of a medical linear accelerator are also needed, as are improved registration systems for going from the real patient to the virtual patient and then back to the real patient for treatment. Other issues that continue to be of concern are data storage and data transfer. Also, a satisfactory process for quantitating the effects of respiratory organ motion or other organ movements has not yet been developed for CT simulation.

For effective use of CT simulation, the radiation oncologist must become familiar with CT cross-sectional anatomy and with the appropriate use of CT contrast materials that aid in the identification of the gross tumor volume and organs at risk. When CT simulation/3DRTTP is first introduced in the clinic, assistance from a diagnostic radiologist in contouring the organs at risk and gross tumor volume/clinical target volumes can be invaluable. However, identifying normal tissues and tumor on a treatment-planning CT can be difficult even for an experienced diagnostic radiologist, as the planning CT images are typically acquired in a nonstandard diagnostic patient position. Since 3D planning requires the definition of target volumes and normal tissue on a CT scan, strong consideration should be given to incorporating image-based, cross-sectional anatomy training into radiation oncology residency training programs. In the interim, short courses on image-based anatomy are needed for practicing radiation oncologists.

While CT is the principal source of image data for 3DRTTP, there is a growing demand to incorporate the complementary information available from magnetic resonance imaging (MRI). The sharply demonstrated tumor–soft-tissue interface often seen on an MRI scan in tumors such as in the brain can be used to better define the gross tumor volume.[13] Several groups have also demonstrated the value of MRI in distinguishing the prostate gland from surrounding normal structures.[14,15] In addition, functional imaging modalities such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) will likely prove to be important in both the target definition phase of treatment planning and also in the follow-up studies needed to assess efficacy. For example, Marks et al have reported on the use of SPECT lung perfusion scans to determine functioning regions of the lung.[16,17] The functional lung volume data are used in calculating dose-volume histograms rather than the CT-defined anatomy and are referred to as functional dose-volume histograms. Radiation beams are planned that minimize irradiation of these functioning areas. Similarly, PET imaging is used to aid in defining the patient’s lung cancer gross tumor volume/clinical target volumes. However, use of multimodality imaging in the treatment planning process brings with it the need for better image registration tools.

Pages: 1  2  3  4  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 52-Year-Old Man Presents With an Erythematous Lesion
Cesar Moran, MD , May 22, 2013

A 52-year-old man presented with an erythematous lesion in the axilla of unknown duration. Surgical excision was performed. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • A 49-Year-Old Woman Develops Thickened and Bound-Down Skin
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Rising PSA Level in a 46-Year-Old Man
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy